Результаты поиска

Cardiovascular Concerns, Cancer Treatment, and Biological and Chronological Aging in Cancer: JACC Family Series.

Cardiovascular disease (CVD) and cancer are leading causes of death globally, particularly among the rapidly growing population of older adults (OAs). CVD is a leading cause of mortality among cancer survivors, often accelerated by cancer treatments associated with short- or long-term cardiotoxicity. Moreover, there is a dynamic relationship among CVD, cancer, and aging, characterized by shared risk factors and biological hallmarks, that plays an important role in caring for OAs, optimizing treatment approaches, and developing preventive strategies. Assessment of geriatric domains (eg, functio

Совпадение в полном тексте источника
… Appetite stimulants and anticachexia drugs are not routinely used in clinical practice because of limited efficacy as well as possible toxicities (eg, thromboembolism with megestrol; altered mental status, muscle wasting, and adrenal insufficiency with prolonged steroid use). 36 There are emerging data …

Unveiling the Link Between Breast Cancer Treatment and Osteoporosis: Implications for Anticancer Therapy and Bone Health.

Background: The interplay between breast cancer treatment and osteoporosis has important consequences for anticancer therapy and patient bone health. Many breast cancer therapies involve hormonal treatments that lower estrogen levels, which can lead to an increased risk of osteoporosis due to reduced bone mineral density. Aromatase inhibitors, chemotherapy, and surgeries such as oophorectomy can further aggravate bone loss, highlighting the necessity of prioritizing bone health during cancer treatment. Objective: This review is aimed at investigating the complex relationship between breast can

Совпадение в полном тексте источника
… buserelin, leuprorelin, and triptorelin) | Antidepressants and serotonin reuptake inhibitors LHRH antagonists (goserelin) | Oral antidiabetics (thiazolidinediones) Antiandrogens (enzalutamide, bicalutamide, flutamide, and nilutamide) | Other osteopenizing drugs Methotrexate | NSAID category drugs Megestrol …

Effects of glucocorticoid replacement therapy in patients with pituitary disease: A new perspective for personalized replacement therapy.

Secondary adrenal insufficiency (SAI) is an endocrine disorder due to impaired secretion of ACTH resulting from any disease affecting the pituitary gland. Glucocorticoid replacement therapy is mandatory to ensure patient survival, haemodynamic stability, and quality of life. In fact, a correct dose adjustement is mandatory due to the fact that inappropriately low doses expose patients to hypoadrenal crisis, while inappropriately high doses contribute to glucose metabolic and cardiovascular deterioration. This review analyses the current evidence from available publications on the epidemiology

Совпадение в полном тексте источника
… Bacterial - Fungal - Parasites - Tuberculosis - Syphilis Traumatic / Vascular - Pituitay apoplexy - Traumatic brain injury - Sheehan’s syndrome - Intrasellar carotid artery - Aneurysm - Subarachnoid haemorrhage Empty sella Iatrogenic / Medications - Surgery - Radiotherapy - Opiates - Glucocorticoids - Megestrol …

Experimental Drugs for Chemotherapy- and Cancer-Related Anemia.

Anemia in cancer patients is a relevant condition complicating the course of the neoplastic disease. Overall, we distinguish the anemia which arises under chemotherapy as pure adverse event of the toxic effects of the drugs used, and the anemia induced by the tumour-associated inflammation, oxidative stress, and systemic metabolic changes, which can be worsened by the concomitant anticancer treatments. This more properly cancer-related anemia depends on several overlapping mechanism, including impaired erythropoiesis and functional iron deficiency, which make its treatment more difficult. Stan

Совпадение в полном тексте источника
… We have previously conducted a randomized controlled clinical trial comparing megestrol acetate alone or with l -carnitine, celecoxib, and antioxidants for the management of cachexia induced by gynecological cancers. …

Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management.

BackgroundObesity or excess body fat is a major global health challenge that has not only been associated with diabetes mellitus and cardiovascular disease but is also a major risk factor for the development of and mortality related to a subgroup of cancer. This review focuses on epidemiology, the relationship between obesity and the risk associated with the development and recurrence of cancer and the management of obesity.MethodsA literature search using PubMed and Google Scholar was performed and the keywords 'obesity' and cancer' were used. The search was limited to research papers publish

Совпадение в полном тексте источника
… Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT04447313 | Phase III | Telephone Delivered Weight Loss, Nutrition, Exercise WeLNES Study NCT05316467 | Phase II/III | Weight Management Plus Megestrol …

Extracellular vesicles in tumor-adipose tissue crosstalk: key drivers and therapeutic targets in cancer cachexia.

Cancer cachexia is a complex metabolic syndrome characterized by unintentional loss of skeletal muscle and body fat. This syndrome is frequently associated with different types of cancer and negatively affects the prognosis and outcome of these patients. It involves a dynamic interplay between tumor cells and adipose tissue, where tumor-derived extracellular vesicles (EVs) play a crucial role in mediating intercellular communication. Tumor cells release EVs containing bioactive molecules such as hormones (adrenomedullin, PTHrP), pro-inflammatory cytokines (IL-6), and miRNAs (miR-1304-3p, miR-2

Совпадение в полном тексте источника
… Currently, the available recommendations for the management of cancer cachexia include a variety of drugs and hormones to (1) improve appetite and reduce nausea (including megestrol acetate, corticosteroids, and ghrelin hormone) (as reviewed in ref [ 5 ] ); (2) increase lean body mass (including selective …

Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy.

The phosphoinositide 3 kinase (PI3K)-protein kinase B (PKB/AKT)-mammalian target of the rapamycin (mTOR) axis is a key signal transduction system that links oncogenes and multiple receptor classes which are involved in many essential cellular functions. Aberrant PI3K signalling is one of the most commonly mutated pathways in cancer. Consequently, more than 40 compounds targeting key components of this signalling network have been tested in clinical trials among various types of cancer. As the oncogenic activation of the PI3K/AKT/mTOR pathway often occurs alongside mutations in other signalling

Совпадение в полном тексте источника
… | 2 | Active, not yet recruiting NCT03072238 (IPATential150) | 1101 Participants Interventional Parallel Assignment | Ipatasertib Abiraterone Placebo | mCRPC | rPFS | 3 | Active, not yet recruiting NCT05538897 | 96 Participants Interventional Randomized Parallel Assignment Open Label | Ipatasertib Megestrol …

Molecular and cellular mechanisms of skeletal muscle atrophy: an update.

Skeletal muscle atrophy is defined as a decrease in muscle mass and it occurs when protein degradation exceeds protein synthesis. Potential triggers of muscle wasting are long-term immobilization, malnutrition, severe burns, aging as well as various serious and often chronic diseases, such as chronic heart failure, obstructive lung disease, renal failure, AIDS, sepsis, immune disorders, cancer, and dystrophies. Interestingly, a cooperation between several pathophysiological factors, including inappropriately adapted anabolic (e.g., growth hormone, insulin-like growth factor 1) and catabolic pr

Совпадение в полном тексте источника
… Despite their long-term application on empirical grounds, appetite stimulants such as antihistaminic drugs, as well as orally active progestational agents (megestrol acetate and medroxyprogesterone acetate) are still evaluated in clinical trials and have been approved for certain indications. …

Clinical Posters From JADPRO Live 2022

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Given the high risk for thromboembolism in these patients, we do not recommend megestrol due to the added risk of clotting. …

Micronutrients in Oncological Intervention.

Nutritional supplements are widely used among patients with cancer who perceive them to be anticancer and antitoxicity agents. Depending on the type of malignancy and the gender 30%-90% of the cancer patients supplement their diets with antioxidant and immuno-stabilizing micronutrients, such as selenium, vitamin C, and vitamin D, often without the knowledge of the treating physician. From the oncological viewpoint, there are justifiable concerns that dietary supplements decrease the effectiveness of chemotherapy and radiotherapy. Recent studies, however, have provided increasing evidence that

Statins: a repurposed drug to fight cancer.

As competitive HMG-CoA reductase (HMGCR) inhibitors, statins not only reduce cholesterol and improve cardiovascular risk, but also exhibit pleiotropic effects that are independent of their lipid-lowering effects. Among them, the anti-cancer properties of statins have attracted much attention and indicated the potential of statins as repurposed drugs for the treatment of cancer. A large number of clinical and epidemiological studies have described the anticancer properties of statins, but the evidence for anticancer effectiveness of statins is inconsistent. It may be that certain molecular subt

Совпадение в полном тексте источника
… After the diagnosis) | Gemcitabine | 106 | NR | NCT00944463 Ovarian cancer | Simvastatin (After the diagnosis) | NR | 20 | NR | NCT04457089 Glioblastoma | Atorvastatin (After the diagnosis) | Radiotherapy/Temozolomide | 36 | NR | NCT02029573 Endometrial cancer | Rosuvastatin (After the diagnosis) | Megestrol …

Molecular mechanisms and clinical management of cancer bone metastasis.

As one of the most common metastatic sites of malignancies, bone has a unique microenvironment that allows metastatic tumor cells to grow and flourish. The fenestrated capillaries in the bone, bone matrix, and bone cells, including osteoblasts and osteoclasts, together maintain the homeostasis of the bone microenvironment. In contrast, tumor-derived factors act on bone components, leading to subsequent bone resorption or excessive bone formation. The various pathways involved also provide multiple targets for therapeutic strategies against bone metastases. In this review, we summarize the curr

Genetic and Mechanistic Insights Inform Amyotrophic Lateral Sclerosis Treatment and Symptomatic Management: Current and Emerging Therapeutics and Clinical Trial Design Considerations.

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder affecting both upper and lower motor neurons. ALS is classically characterized by painless progressive weakness, causing impaired function of limbs, speech, swallowing, and respiratory function. The disease is fatal within 2-4 years, often the result of respiratory failure. The pathologic hallmark for a majority of ALS cases is aberrant cytoplasmic accumulations of the nuclear protein TAR-DNA binding protein (TDP-43). A total of 10-15% of ALS can be attributed to a single gene mutation, known as genetic or "familia

Совпадение в полном тексте источника
… | -Dizziness -Drowsiness -Nausea/vomiting -Paranoia/changes in thinking -Euphoria | -Heart rate, blood pressure -Mood | -May exacerbate depression -May cause syncope with dose initiation -Cost may be prohibitive to patients -Nonregulated forms of THC face legal, safety, and dose-reliability issues Megestrol …

Abstracts of the 5(th) Cachexia Conference, Barcelona, Spain, December 5-8, 2009.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Biology and Diseases of Dogs

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Molecular Inhibitors of Growth Signals

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Резюме МКАРЕ 2023 77th Национальный конгресс " СИААРТИ "

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Р

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Integumentary System

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Abstracts of the 28th Annual San Antonio Breast Cancer Symposium, December 8-11, 2005, San Antonio, Texas, USA.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.